Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)

NCT02814175 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02814175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02814175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
August 5, 2016
Completion date
March 19, 2020
Enrollment
246 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis